What Ozempic really does to your face: All the tell-tale signs of using skinny jabs, from bigger lips to sunken eyes
The Ozempic boom has seen a drug widely used to treat diabetes and manage obesity in adults transform into 'miracle' weight loss jab that's coveted by anyone with a few extra kilos to shed.
Ozempic and other alternatives like Mounjaro and Wegovy are all different brand names for the drug semaglutide that mimics the the actions of GLP-1 - a hormone in the brain that regulates appetite and feelings of fullness.
Weekly doses of these blockbuster weight loss medicines can help people shed 15 to 20 per cent of their body weight on average - but it can also pile on the years and make you look older than you are, experts say.
The rapid and drastic weight loss triggered by these medicines has left people 'freaking out' about developing so-called 'Ozempic face', celebrity nutritionist Rose Ferguson told Femail.
The 49-year-old former model, who is close friends with Kate Moss and boasts 116,000 followers on Instagram, reported a rise in the number of her clients who are worried about their face transfroming from these injections.
Semaglutide, which is not a targeted drug, does not just cause loss around the stomach and thighs, but the entire body - including the face.
This means that, although it has helped millions around the world achieve their weight loss goals, the 'skinny shot' can also famously make users look extremely gaunt over time - a phenomenon critics have unflatteringly labelled 'Ozempic face'.
But how exactly does Ozempic manifest? Dermatologists, aestheticians and cosmetic surgeons break down the tell-tale signs to watch for, as more information about the drug's side effects become known.
More visible wrinkles
People using skinny jabs like Ozempic might notice a greater number of wrinkles all over their visage - including on the forehead - as these 'miracle' weight loss treatments cause a loss of volume in the face.
According to New York-based cosmetic dermatologist Dr Michele Green, 'this volume loss can also worsen the appearance of existing fine lines, wrinkles, and skin laxity' and, therefore, contribute to a more 'aged' look with continued use.
Eyes sink
Experts also pointed out how Ozempic can make your eyes look more sunken as a result of rapid weight loss - with people reporting anywher
Speaking to DailyMail.com, US-based plastic surgeon pointed out a 'hollowing under the eyes' and 'more wrinkles' and fine lines around them as the weight loss drug begins to show results.
Noting how the face of Robbie Williams, who admitted to taking 'something like Ozempic' to shed pounds and manage his 'type-2 self-loathing', she added: 'With Robbie, you can see the direct results of weight loss.'
Cheeks sag
When you lose weight over an extended period of time, it allows the skin to contract and shrink with the body - but drugs like Ozempic significantly accelerate the process.
And while this weight loss reduces facial or subcutaneous fat - as well as making the body leaner - it also leads to loose skin because it hasn't had enough time to retract.
This leads to cheeks that sag or droop, and is one of the main characteristics of 'Ozempic face'.
'By depleting the subcutaneous fat, the skin appears thinner, with more wrinkling and often lipstick lines,' New York-based plastic surgeon Dr Barry Weintraub told this website.
Lips get bigger
While the most common symptoms of this condtion include drooping around the cheeks, sunken eyes, and an increased number of wrinkles, a plumper, more pronounced pout can also occur in people who have injectable fillers.
Speaking to MailOnline, aesthetician Kayti Brooks said that 'Ozempic face' makes lip fillers look more pronounced.
The expert - who runs Grey Door Aesthetics in Hove - said: 'Losing weight at the phenomenal rate Ozempic allows will lose the fat all over the body including the face - but overfilled lips will not shrink.
'Any filler won't have the support structure of the skin. The filler will stay and the lips stay big or bigger! With the skin laxity disappearing the client may feel the need to plump up with filler.
'This is hugely ageing and so obvious what procedures have been carried out.'
Folds at the corner of the mouth
Dr Green told DailyMail.com that 'Ozempic mouth' is something she is seeing among many of her clients taking the blockbuster weight loss medication.
She said: 'Many users of Ozempic who I know report noticeable volume loss in the face, which can result in the formation of fine lines, wrinkles, sagging skin, and jowls around the mouth.
The condition is considered part of a broader phenomenon dubbed 'Ozempic face' where rapid weight loss causes sagging in the cheeks and around the mouth.
Dr Green noted that the appearance of an aged mouth is especially apparent on people who rapidly lose weight from higher doses of the GLP-1 drug.
It is characterised by deep folds at the corners of the mouth, increased vertical wrinkles on the lips, sagging skin around the borders of the lips and and drooping skin around the chin.
Dr Green has noticed a number of celebrities suffering from Ozempic mouth as the result of taking weight loss drugs, with some of her standout examples being Sharon Osbourne, Rebel Wilson and Whoopi Goldberg.
Tooth decay
The latest side effect linked to the use of skinny jabs is tooth decay, with experts noting a rise in the number of patients complaining of 'Ozempic teeth'.
The unofficial umbrella term refers to dental problems such as tooth decay and gum disease linked to these weight loss drugs that are now used by millions across the world.
'While there is no direct scientific evidence yet, in clinical settings semaglutide drugs like Ozempic are starting to show correlation with damaged teeth,' Dr Sandip Sachar, a dentist, told The Standard.
Experts told the outlet there could be a couple of different reasons for this.
First, GLP-1 receptor agonists like Ozempic can lead to less saliva being produced and, consequently, hinder the mouth's self-cleansing abilities.
The second reason is linked to acid reflux, a common side-effect of these jabs. An increase in the amount of acid 'can erode your teeth,' Dr Daniel Atkinson, clinical lead at Treated.com, told the paper.
Finally, Ozempic's appetite-suppression qualities can make it difficult for the body to get the nutrients it requires to maintain healthy teeth.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scottish Sun
13 minutes ago
- Scottish Sun
New Ozempic alternative only needs to be taken once a month and leads to ‘substantial weight loss'
Patients taking the drug lost 16 per cent of their body fat over the course of a year NO WEIGH New Ozempic alternative only needs to be taken once a month and leads to 'substantial weight loss' A NEW weight loss jab that only needs to be taken once monthly leads to "substantial weight loss", according to early trials. Drugs like Wegovy and Mounjaro - or diabetes jab Ozempic - need to be injected once weekly to see results. Advertisement 1 A new weight loss jab currently being trialled only needs to be given once a month Credit: PA But a new drug currently being trialled by pharmaceutical company Amgen can be given once a month and saw users shed up to 16 per cent of their body weight over the course of a year. This is bellow the 20 per cent weight loss than can be achieved through Mounjaro - dubbed the 'King Kong' of weight loss jabs - over 18 months. But scientists behind the new trial said the less frequent dose schedule could encourage people to stick to the treatment. The drug is called maridebart cafraglutide, or MariTide for short. Advertisement Like Wegoy, Mounjaro and Ozempic, it's a glucagon-like peptide-1 (GLP-1) receptor agonist, meaning it targets the GLP-1 receptors in the brain and pancreas to reduce appetite and control blood sugar. But it also targets glucose-dependent insulinotropic polypeptide (GIP) receptors, which are also involved in managing insulin release, fat storage, metabolism, and appetite. This is part of the reason the drug needs to be administered less often. "In this phase two trial, once-monthly maridebart cafraglutide resulted in substantial weight reduction in participants with obesity with or without type 2 diabetes," they wrote in The New England Journal of Medicine. Advertisement "Once-monthly therapeutics for obesity may offer sustainable treatment for persons with this highly prevalent, chronic disease. "Medication at less frequent intervals may improve adherence and reduce barriers, potentially facilitating improvements in long-term health outcomes." I went on fat jabs but the hair loss was unbelievable so I quit - I'd rather be chubby with hair than skinny and bald There were 592 people aged 18 or older enrolled in the study - 465 of them were obese, defined as having a BMI of 30 or more, or a BMI of 27 with one obesity-related complication. The remaining participants had obesity as well as type 2 diabetes. Advertisement They were randomly given monthly maridebart cafraglutide injections or a placebo for a year, at dose of 140, 280, or 420 mg. Some participants remained on a stable dose throughout, while others gradually worked up to a higher one. Participants were asked to report any side effects they experienced from the drug, such as nausea, vomiting, retching, headaches, diarrhoea and constipation Those with obesity lost 12.3 to 16.2 per cent of their body weight while taking maridebart cafraglutide over 52 weeks, compared to people taking a placebo who only lost 2.5 per cent of their weight. Advertisement As for people with diabetes and obesity, they lost 8.4 to 12.3 per cent of their body weight on the drug, compared to 1.7 per cent weight loss for placebo-takers. Almost all participants taking maridebart cafraglutide experienced at least one side-effect from the drug - mild to moderate nausea, vomiting and retching were the most frequently reported side-effects. These effects were less severe when participants gradually built up to a full dose of maridebart cafraglutide, which may be the best way to get people started on it in the future. Advertisement Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines. Two deaths were reported in participants who received maridebart cafraglutide, but both were investigated and deemed unrelated to the drug. A handful of people taking the drug reported gallbladder issues, which can also be an issue with other weight loss jabs. Some also experienced depression and suicidal thoughts while participating in the trial. One person taking maridebart cafraglutide and one person on the placebo drug withdrew as a result. This was a phase two clinical trial, meaning it still needs to be tested on a bigger group of participants over a longer time period. Advertisement Amgen deemed the results promising enough to progress to a phase three trial. "This phase two dose-ranging trial investigating the efficacy and safety of maridebart cafraglutide, a long-acting GLP-1 receptor agonist and GIP receptor antagonist administered once monthly or less frequently, showed substantial weight reduction and no new or unexpected safety signals, supporting advancement to phase three," researchers wrote. They estimated MariTide could lead to even more weight loss, beyond a year of use. "A weight plateau was not reached at 52 weeks, with weight continuing a downward trajectory," they noted. Advertisement "Therefore, longer-term trials are needed to assess the full weight efficacy of this agent."
The Sun
14 minutes ago
- The Sun
New Ozempic alternative only needs to be taken once a month and leads to ‘substantial weight loss'
A NEW weight loss jab that only needs to be taken once monthly leads to "substantial weight loss", according to early trials. Drugs like Wegovy and Mounjaro - or diabetes jab Ozempic - need to be injected once weekly to see results. 1 But a new drug currently being trialled by pharmaceutical company Amgen can be given once a month and saw users shed up to 16 per cent of their body weight over the course of a year. This is bellow the 20 per cent weight loss than can be achieved through Mounjaro - dubbed the 'King Kong' of weight loss jabs - over 18 months. But scientists behind the new trial said the less frequent dose schedule could encourage people to stick to the treatment. The drug is called maridebart cafraglutide, or MariTide for short. Like Wegoy, Mounjaro and Ozempic, it's a glucagon-like peptide-1 (GLP-1) receptor agonist, meaning it targets the GLP-1 receptors in the brain and pancreas to reduce appetite and control blood sugar. But it also targets glucose-dependent insulinotropic polypeptide (GIP) receptors, which are also involved in managing insulin release, fat storage, metabolism, and appetite. This is part of the reason the drug needs to be administered less often. "In this phase two trial, once-monthly maridebart cafraglutide resulted in substantial weight reduction in participants with obesity with or without type 2 diabetes," they wrote in The New England Journal of Medicine. "Once-monthly therapeutics for obesity may offer sustainable treatment for persons with this highly prevalent, chronic disease. "Medication at less frequent intervals may improve adherence and reduce barriers, potentially facilitating improvements in long-term health outcomes." There were 592 people aged 18 or older enrolled in the study - 465 of them were obese, defined as having a BMI of 30 or more, or a BMI of 27 with one obesity-related complication. The remaining participants had obesity as well as type 2 diabetes. They were randomly given monthly maridebart cafraglutide injections or a placebo for a year, at dose of 140, 280, or 420 mg. Some participants remained on a stable dose throughout, while others gradually worked up to a higher one. Participants were asked to report any side effects they experienced from the drug, such as nausea, vomiting, retching, headaches, diarrhoea and constipation Those with obesity lost 12.3 to 16.2 per cent of their body weight while taking maridebart cafraglutide over 52 weeks, compared to people taking a placebo who only lost 2.5 per cent of their weight. As for people with diabetes and obesity, they lost 8.4 to 12.3 per cent of their body weight on the drug, compared to 1.7 per cent weight loss for placebo-takers. Almost all participants taking maridebart cafraglutide experienced at least one side-effect from the drug - mild to moderate nausea, vomiting and retching were the most frequently reported side-effects. These effects were less severe when participants gradually built up to a full dose of maridebart cafraglutide, which may be the best way to get people started on it in the future. Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines. Two deaths were reported in participants who received maridebart cafraglutide, but both were investigated and deemed unrelated to the drug. A handful of people taking the drug reported gallbladder issues, which can also be an issue with other weight loss jabs. Some also experienced depression and suicidal thoughts while participating in the trial. One person taking maridebart cafraglutide and one person on the placebo drug withdrew as a result. This was a phase two clinical trial, meaning it still needs to be tested on a bigger group of participants over a longer time period. Amgen deemed the results promising enough to progress to a phase three trial. "This phase two dose-ranging trial investigating the efficacy and safety of maridebart cafraglutide, a long-acting GLP-1 receptor agonist and GIP receptor antagonist administered once monthly or less frequently, showed substantial weight reduction and no new or unexpected safety signals, supporting advancement to phase three," researchers wrote. They estimated MariTide could lead to even more weight loss, beyond a year of use. they noted.
Daily Mail
29 minutes ago
- Daily Mail
Scientists pinpoint diet tweak that can help people lose 1lb a week without counting calories
Ditching meat for a just a few months could help you lose almost a pound a week, shock new research has suggested. US scientists found that overweight adults who went vegan for roughly four months were just over 13lbs (6kg) lighter by the end of the study. They credited the slimming effect to plant-based diets—those devoid of meat, dairy and eggs—producing less acid during digestion. Researchers said the higher levels 'dietary acid' produced by animal products increased inflammation in the body. This in turn disrupts the delicate internal processes in the body— like the metabolism and hormone production—contributing to weight gain, they explained. Dr Hana Kahleova, an expert in nutrition from the Physicians Committee for Responsible Medicine in Washington and lead author of the new study, claimed the findings show the benefits of embracing veganism. 'Replacing animal products with plant-based foods like leafy greens, berries, and legumes can help promote weight loss and create a healthy gut microbiome,' she said. In the study, 62 overweight adults were put on either a vegan-diet or the health-focused Mediterranean diet for 16 weeks. The latter emphasises eating fresh vegetables, healthy fats such as those from olive oil and nuts and lean meats like fish and chicken. Participants' body weight was measured before and after the diet. Then—after a four week break—the group did another 16 weeks on the other diet. This allowed researchers to compare weight loss across the two diets using the same participants. Scientists also compared the 'dietary acid' scores of the foods the participants consumed across the two diets. At the study's conclusion, the vegan diet saw participants lose an average of 13.2 lbs (6kg) in 16 weeks, roughly 13oz (375g) per week. By contrast, those on the Mediterranean diet didn't experience any significant weight loss, the authors said. Writing in the journal the Frontiers in Nutrition, they recommended dieters looking to slim down to incorporate more fruit, vegetables and grains that counteract dietary acid— a process called alkalising—into their diet. The team specifically highlighted vegetables like leafy greens, broccoli, beets, asparagus, garlic, carrots, and cabbage. For fruits, they recommended berries, apples, cherries, apricots, or melons. Researchers also said legumes like lentils, chickpeas, peas, beans, soy products such as tofu and alternative grains like quinoa or millet could also have this effect. While Britons have been told for years to up their intake of fresh fruit and vegetables and cut down of fatty cuts and processed meats for their health, there are some health hazards to going completely vegan. Nutritionists have previously warned that vegans can miss out on a range of key vitamins and minerals by shunning animal products. These include a lack of vitamin B12, which is in found milk and eggs, which can lead to fatigue or tiredness and negatively impact mental health. Vitamin D is another nutrient found mainly in animal products, like oily fish, that those on vegan diets can be deficient in. A vitamin D deficiency can lead to issues with bone development and cause pain. A lack of iron, found in red meat and liver, can also lead to anaemia, causing people to feel tired and have heart palpitations. Iodine, mainly found in seafood, is another nutrient known to be lacking in vegan diets and is important in maintaining a health metabolism. While plant-based diets can include all of these mentioned nutrients, vegans need to carefully manage what they eat, or take supplements, to ensure they get enough. There have also been concerns about the potential health impacts of fake 'meats' in vegan diets. Last year, British experts found those who ate plant-based versions of sausages, burgers and mince seemingly had worse blood pressure than their meat-consuming counterparts Another recent UK study revealed that opting for ultra-processed plant foods, like vegan sausages and burgers, as well as cakes and crisps, was linked to a 15 per cent higher risk of suffering heart attacks and strokes. Interest in a plant-based diet has soared in recent years, with vegans citing ethical, environmental or health reasons. The exact numbers of vegans now in the UK is almost impossible to establish. But one recent survey suggested around 600,000 people are believed to be on a plant-based diet. In England, one in four adults are now obese, while just over three in five are overweight. However, four out of five adults are either overweight or obese in some areas of the country. The NHS recommends that those overweight wanting to lose weight focus on consuming fewer calories overall and eating more healthily while upping the amount of weekly exercise. The health service cautions that using what it dubs 'fad diets' may lead to short term weight loss this is rarely sustainable.
